APOB and type 2 diabetes mellitus: We detected that anti-ApoB IgM plasma levels were significantly decreased in patients with T2DM (Figure 5B) and the MS (Figure 5F) but were not modulated by smoking status (Figure 5C), arterial hypertension (HTN, Figure 5D), or obesity (Figure 5E).